IFNG and neoplasm: IFN-γ, vital for anti-tumor effects, loses effectiveness when tumors acquire JAK1/2 loss-of-function mutations, hindering IFN-γ-induced PD-L1 expression and MHC-I molecules [79, 82, 83].